Key highlights

  • PainChek (ASX:PCK) reported quarterly unaudited customer Revenue of AUD 1.210 million.
  • The Silverado paid pilot covered 203 licences across two US sites.
  • A separate UK agreement covers about 1,800 licences in 23 homes.

PainChek (ASX:PCK) was quoted at AUD 0.060, a decline of 10.45% during the session on 20 November 2026. The S&P/ASX 200 also traded lower during the session. The company, a developer of digital pain assessment software, reported a revised aged care sales strategy and September-quarter metrics on 28 October 2026.

New operators add to the aged care pipeline

PainChek’s 28 October 2026 Quarterly Report outlined its focus on residential aged care in priority markets. In the US, it signed a paid pilot with Silverado covering 203 licences across two sites. Further rollout would depend on evaluation and additional agreements. Silverado’s broader network comprises 31 sites, and PainChek described a possible opportunity for up to 2,500 licences. After quarter end, Sabra expanded to 23 contracted sites across five operators covering 808 licences. The pilot, contracted site count and potential group-wide opportunity describe different stages of customer engagement and carry different degrees of commitment.

The UK deal and activated licence base

Hallmark Luxury Care Homes signed an agreement after quarter end covering about 1,800 licences across its 23 homes in England and Wales. PainChek reported 91,323 activated licences and activated annual Recurring Revenue of AUD 4.514 million at September end. Each was up 1.2% on the preceding quarter. Compared with the corresponding period, they rose 27.3% and 31.1% respectively. The company explained that its current revenue and activated metrics largely reflect agreements signed earlier, because customer implementation and commencement of billing take time. A newly signed agreement can therefore enter activated licence totals over more than one reporting period.

Revenue, usage and cash receipts

Unaudited customer revenue was AUD 1.210 million, up 12.9% on the preceding quarter and 42.4% year on year. Customer receipts were AUD 1.045 million and quarter-end cash was AUD 4.269 million. The company recorded net operating cash outflow of AUD 1.714 million, including receipt of AUD 1.136 million in government grants and tax incentives. Activated customer sites reached 2,076, cumulative assessments reached 24.49 million and reported retention improved to 90%. Those activity and cash metrics record different aspects of operations. The revenue result and new contracts need to be read against the pace of customer onboarding. Four customers had each passed one million assessments. Bolton Clarke, Anglicare, BaptistCare and Dovehaven together accounted for more than 6.1 million assessments across Australia and the UK.

Sales changes aim to shorten activation time

The commercial reset included changes to leadership, operations and customer-facing teams. PainChek said it is concentrating resources on selected US residential aged care opportunities, UK growth and its existing Australia and New Zealand market. It is also agreeing activation and billing dates in new contracts. The timing of customer implementation and the outcome of the Silverado pilot remain important to how new contracts translate into activated licences and receipts. An increase in cumulative assessments describes use of the application, while active contracts and cash receipts measure other parts of the commercial process.

PainChek identified customer Training and staged site implementation as ways to broaden adoption, particularly where operators start with an initial evaluation at selected sites.

Why the strategy favours residential aged care

The company estimated its priority residential aged care market at approximately 2.19 million potential licences, with an estimated Market Value of AUD 190 million. Those are company estimates of market size, distinct from contracted or activated customers. The team reported a larger potential market that includes hospitals, skilled nursing and home care, but assigned immediate priority to residential aged care, where it cited existing deployments and integration experience. In the core US residential setting, PainChek said adoption does not depend on a dedicated reimbursement code for its application. A provider still needs to evaluate the service, put the technology into use and begin billing under the relevant agreement. The US pilot and UK contract illustrate different starting points along that commercial process, with pilot evaluation and site activation each capable of changing the timing of reported licences and revenue.

The next evidence is activation and billing

The next operating figures can show how much of the newer US and UK Business has gone live and whether revenue and cash receipts are increasing alongside licence activation. Pilot outcomes and the timing of subsequent agreements will give further information on potential rollout beyond the two Silverado sites.